In both DLBCL and CLL, upregulation of PIK3CG may lead to abnormal activation of the PI3K signaling pathway, promoting cancer cell proliferation and survival and inhibiting cell apoptosis, and thus promoting disease progression. This evidence concerns the gene PIK3CG and diffuse large B-cell lymphoma.